How Do Home and Clinic Blood Pressure Readings Compare in Pregnancy?

A Systematic Review and Individual Patient Data Meta-Analysis


Abstract—Hypertensive disorders during pregnancy result in substantial maternal morbidity and are a leading cause of maternal deaths worldwide. Self-monitoring of blood pressure (BP) might improve the detection and management of hypertensive disorders of pregnancy, but few data are available, including regarding appropriate thresholds. This systematic review and individual patient data analysis aimed to assess the current evidence on differences between clinic and self-monitored BP through pregnancy. MEDLINE and 10 other electronic databases were searched for articles published up to and including July 2016 using a strategy designed to capture all the literature on self-monitoring of BP during pregnancy. Investigators of included studies were contacted requesting individual patient data: self-monitored and clinic BP and demographic data. Twenty-one studies that utilized self-monitoring of BP during pregnancy were identified. Individual patient data from self-monitored and clinic readings were available from 7 plus 1 unpublished articles (8 studies; n=758) and 2 further studies published summary data. Analysis revealed a mean self-monitoring clinic difference of ≤1.2 mmHg systolic BP throughout pregnancy although there was significant heterogeneity (difference in means, I² >80% throughout pregnancy). Although the overall population difference was small, levels of white coat hypertension were high, particularly toward the end of pregnancy. The available literature includes no evidence of a systematic difference between self and clinic readings, suggesting that appropriate treatment and diagnostic thresholds for self-monitoring during pregnancy would be equivalent to standard clinic thresholds. (Hypertension. 2018;72:686-694.

DOI: 10.1161/HYPERTENSIONAHA.118.10917.)

Key Words: blood pressure ■ hypertension ■ pre-eclampsia ■ pregnancy ■ white coat hypertension

Worldwide, ≈10% of women have high blood pressure (BP) during pregnancy.¹ Hypertensive disorders in pregnancy (HDP), including preeclampsia, are one of the commonest causes of maternal mortality² and are a leading cause of direct maternal deaths in the United Kingdom.³,⁴ Hypertension is commonly defined as systolic BP of ≥140 mmHg or diastolic BP 290 mmHg. If hypertension presents after 20 weeks gestation, it is known as gestational hypertension, and when combined with the presence of maternal organ dysfunction, uteroplacental dysfunction, or significant proteinuria (>300 mg proteinuria/24 hours or >30 mg/mmol creatinine [protein-creatinine ratio]), it is known as preeclampsia.⁵,⁶ Preeclampsia complicates 2% to 8% of all pregnancies and up to 25% of pregnancies in women with chronic hypertension.¹² Current guidelines identify risk factors for preeclampsia based on medical and family histories.⁶,¹³ The UK guidelines

Received February 13, 2018; first decision February 26, 2018; revision accepted June 22, 2018.

From the Nuffield Department of Primary Care Health Sciences (K.L.T., C.B., R.S., C.H., C.C., K.S.T., R.J.M.) and Bodleian Health Care Libraries (N.R.), University of Oxford, United Kingdom; Institute of Applied Health Research, University of Birmingham, United Kingdom (J.H.); Obstetric, Medicine Division, Department of Obstetrics and Gynecology, CHU Ste-Justine, Montreal, Quebec, Canada (É.R.); Omnicare Women’s Health Centre, Auckland, New Zealand (C.L.); Guy’s and St Thomas’ NHS Foundation Trust, Department of Women’s Health, St Thomas’ Hospital, London, United Kingdom (M.C.); Department of Obstetrics and Gynaecology, Faculty of Medical and Health Sciences, The University of Auckland, New Zealand (R.S.T., J.W.); Auckland City Hospital, New Zealand (R.A.N.); Fetal Medicine Unit, St George’s University Hospitals NHS Foundation Trust, London, United Kingdom (A.K.); Department of Obstetrics and Gynecology, The George Washington University School of Medicine and Health Sciences, DC (K.M.); Royal Victoria Infrmary, Newcastle upon Tyne, United Kingdom (J.W.); Department of Obstetrics and Gynecology, Faculty of Medical and Health Sciences, University of Auckland, New Zealand (J.W.); Department of Renal Medicine; St. George Hospital and University of NSW, Sydney, Australia (M.B.); and Oxford University Hospitals NHS Foundation Trust, Women’s Centre, John Radcliffe Hospital, Oxford, United Kingdom (L.M.).

The online-only Data Supplement is available with this article at https://www.ahajournals.org/doi/suppl/10.1161/HYPERTENSIONAHA.118.10917. Correspondence to Richard J. McManus, Nuffield Department of Primary Care Health Sciences, Radcliffe Observatory Quarter, Woodstock Rd, University of Oxford, OX2 6GG, United Kingdom. Email richard.mcmanus@phc.ox.ac.uk

© 2018 The Authors. Hypertension is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution-Non-Commercial-NoDerivs License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made.

Hypertension is available at https://www.ahajournals.org/journal/hyp

DOI: 10.1161/HYPERTENSIONAHA.118.10917
recommend BP monitoring with increased frequency in those at higher risk of preeclampsia.6 Despite this, women still develop preeclampsia in the interval between antenatal visits, and a significant proportion of subsequent deaths occur after HDP, which developed after apparently normal antenatal visits.14 Reliance on intermittent clinic measurements may lead to both false-positive (white coat hypertension [WCH]) and -negative (masked hypertension) interpretations. Enhanced identification of developing hypertension among higher risk women could improve outcomes.

Self-monitoring of BP (SMBP), where individuals measure their own BP in a home setting, allows multiple measurements for several days with little disturbance of lifestyle and is now commonplace in adults with hypertension.15–17 Regular SMBP might improve detection of hypertension in the pregnant population while reducing the time, money, and inconvenience of frequent appointments, without compromising the ability to detect and monitor a potentially serious disease. Potential advantages of SMBP include more frequent BP monitoring, improved accuracy, and increased acceptability to pregnant women.18,19

The importance and potential of self-monitored BP measurement has been noted in both a joint statement from the American Heart Association, American Society of Hypertension, and Preventive Cardiovascular Nurses Association and the recent European Society of Hypertension guidelines.20 Consequently, in some countries, SMBP during pregnancy is becoming common: a Canadian pilot survey found >60% of women diagnosed with nonproteinuric hypertension in pregnancy were already SMBP.21 A subsequent survey, of Canadian obstetricians and primary care physicians, found that most used SMBP to check for WCH (where BP is higher in clinic than at home) rather than ambulatory BP monitoring.22

Thresholds for SMBP in the hypertensive nonpregnant population are generally lower than when using clinic monitoring, but the clinic–home difference varies dependent on the population,23,24 and general populations have been shown to have minimal differences between home and clinic readings.25,26 Recent guidelines from the society of Obstetrician and Gynaecologists of Canada suggest a self-monitoring threshold of 135/85 mm Hg.27 However, there are limited data on SMBP monitoring during pregnancy to guide such recommendations. This study aimed to systematically review the available evidence for differences between self-monitored and clinic BP during pregnancy and investigate this using individual patient data (IPD) where available.

Methods

Data Availability
Data were obtained from third parties for this project. Several of the participating studies required specific data sharing agreements from their host institution. Current agreements are for the purposes of this analysis alone, and as such new approval would be required. Requests for Data Sharing should be directed to information.guardian@phc.ox.ac.uk. Such requests will be considered by all data holders involved in this collaboration. There were no specific study materials.

Search Strategy for Identification of Studies
The searches were run from database inception to July 2016, using a combination of title/abstract keywords and subject headings for self-measurement, BP, and pregnancy (Figure S1 in the online-only Data Supplement). No date or publication date limits were applied. We searched the Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of Effectiveness, Cochrane Central Register of Controlled Trials (The Cochrane Library, Wiley), Medline (OvidSP; 1946–present), Embase (OvidSP; 1974–present), CINAHL (EbscoHOST; 1980–present), PsycINFO (OvidSP; 1967–present), Science Citation Index Expanded, Social Sciences Citation Index, Conference Proceedings Citation Index-Science & Conference Proceedings Citation Index-Social Science & Humanities (Web of Knowledge; 1945–present).

Inclusion Criteria
All primary studies of any study design that included SMBP during pregnancy in a sample of multiple women were included. Each corresponding author was contacted requesting IPD or summary data for self-monitored and clinic BP. Studies that provided clinical and self-monitored data or published sufficient data to allow comparison were included in the analysis. This study was registered on Prospero: CRD42016050528.

Data Extraction
Two reviewers (K.T. and J.H.) independently reviewed the titles and abstracts of identified articles and, after assessment of the full text of potentially relevant papers, extracted data (Figure S2). Data extraction included a methodological quality assessment adapted from the Quality Assessment of Diagnostic Accuracy Studies checklist28—clear selection criteria for participants, response rate, validation of sphygmomanometer, validation of self-monitored readings, and blinding of those performing clinic measurements. Data extractions were performed in duplicate and disagreements resolved by consensus.

Individual Patient Data
Authors from all eligible studies were approached to provide anonymized IPD. The data were considered at 4 time periods (5–14, 15–22, 23–32, and 33–42 weeks’ gestation), and these were chosen to enable the inclusion and analysis of relevant comparative data from included studies throughout pregnancy. A trimester-based comparison would have resulted in loss of data or inappropriate comparisons.

Data Analysis and Statistical Methods
The absolute differences in BP between clinic and self-measurements were calculated (means and SDs) across all studies and in subgroups according to gestational stage. These differences were calculated using the nearest (closest in time, within 3 days either side) clinic and self-monitored readings for each woman in each comparison period, including only one comparison per woman per stage (5–14, 15–22, 23–32, and 33–42 weeks) to avoid bias toward women who completed more readings than others.

Meta-analysis was undertaken in Stata13 (StataCorp, LP) to create forest plots, and the I² statistic was used to estimate statistical heterogeneity for each outcome. IPD data were used to calculate the means of differences. A subgroup analysis of normotensive and hypertensive participants (based on clinic BP ≥140/90 mmHg) was completed to examine differences between the groups. To compare with aggregate data, the difference in means was also calculated. Where substantial heterogeneity was detected, the direction of effect was assessed, and potential reasons for heterogeneity were considered. A random-effects analysis was used, and differences between self-monitored and clinic readings were assessed using scatter and Bland-Altman plots.

Definitions
There was no evidence before this work to guide the definitions of hypertension on the basis of home readings. In general unselected populations, there is little difference between home and clinic readings.29,30,31 The results from the review, which included mixed populations of both normotensive and hypertensive women, suggested little overall difference between home and clinic readings. Current UK and international guidelines use a clinic threshold of 140/90 mmHg for diagnosing hypertension during pregnancy. For the purposes of this
work, true hypertension was considered present when self-monitored and clinic readings both had systolic BP ≥140 and diastolic BP ≥90 mm Hg in the comparison period. Masked hypertension was defined as normotensive clinic BP <140/90 mm Hg with self-monitored readings of systolic BP ≥140 or diastolic BP ≥90 mm Hg. Finally, WCH was defined as clinic systolic BP ≥140 mm Hg and diastolic BP ≥90 mm Hg with normotensive self-monitored readings (<140/90 mm Hg). Recognizing that home monitoring thresholds for hypertension suggested for the nonpregnant hypertensive population are lower (135/85 mm Hg), a sensitivity analysis was performed using a home threshold for hypertension of 135/85 mm Hg.

Results

Findings From the Systematic Review

From 2654 journal articles identified, 121 were assessed in full. Twenty-one articles included SMBP during pregnancy in a sample of multiple women. Corresponding authors were contacted requesting IPD or summary data for self-monitored and clinic BP; there was no reply from 4 and a further 10 were unable to provide IPD, leaving 7 studies (6 authors) where investigators provided BP data from both self-monitoring and clinic BP during pregnancy (n=596; Figure 1).32–34 One further study undertaken by our group and not published in full at the time was included (n=162; total 758).35 Of the 10 studies unable to provide data, 2 had published summary data of self-monitored clinic comparison (Table 1).36,37

Characteristics of Studies Included in the IPD Analysis

Included studies were performed between 2002 and 2017 on a range of populations, including women with a healthy pregnancy,31,38 women with suspected hypertension,29,30 and those with known gestational hypertension or preeclampsia.31,32,34 Considerable variation was seen in both monitoring schedules and the gestation period when the readings were taken. Only 2 studies used a monitor that had passed validation testing in pregnancy (Table 2).34,35

Difference Between Self-Monitored and Clinic Readings Though Pregnancy

IPD from the 8 included studies (n=758),29–35,38 contained BP readings throughout pregnancy (Figure 2). The overall mean differences between home and clinic readings appeared small throughout pregnancy (Table 3), with mean of differences between 1.5 to 2.2 mm Hg systolic (Figure 2) and 0.7 to 1.5 mm Hg diastolic BP (Figure S3). However, there was significant heterogeneity between studies (I² >80 at all gestational stages for systolic BP), which was only slightly improved by removal of single studies.

Subgroup analysis of normotensive and hypertensive groups showed that normotensive pregnant women have little differences between home and clinic readings with mean differences between −0.6 and 1.2 mm Hg systolic (Figures S9 and S10) and −0.6 and 0.7 mm Hg diastolic. Hypertensive women, however, had much larger differences between home and clinic (Figures S7 and S8). The heterogeneity remained high, and the number of hypertensive participants included at the early stages of pregnancy was low.

Differences in means (office and home) were plotted for both the IPD data and summary data from other studies where possible (Figures S4 and S5).36,37 Reported differences in means were higher from studies for which IPD data were not available (4.06 mm Hg at 15–22/40 and 2.9 mm Hg at 23–32/40).36,37

Influence of Absolute BP on Mean Difference Between Self-Monitored and Clinic Readings

Bland-Altman and scatter plots show good agreement between self-monitored and clinic BP across the range of both systolic and diastolic pressures (Figure 3; Figure S6). At later gestation, the number of readings above the limits of agreement were higher than in early pregnancy (Figure 3).

Prevalence of True and WCH by Gestation

As gestation increased, mean clinic BP initially remained low, and then began to rise from 33 weeks gestation. Using a threshold of ≥140/90 mm Hg for hypertension for both clinic and self-monitored BP, the prevalence of true hypertension and WCH increased with gestation. At 33 to 42 weeks, the prevalence of WCH and true hypertension was similar, indicating women with hypertension on clinic measurements were as likely to have normal BP when self-monitoring as they were to have true hypertension (Table 3). A sensitivity analysis of a self-monitored 135/85 mm Hg threshold is shown in Table S1.

Discussion

This systematic literature review identified 21 studies that included SMBP during pregnancy. IPD were available for both self-monitored and clinic BP readings from 8 studies (758 patients).29–35,38 Comparison of self-monitored and clinic readings revealed no clinically relevant difference throughout pregnancy, with significant heterogeneity between studies that may be accounted for by the varying populations.
Interestingly, although overall differences between self-monitored and clinic pressure were small, the prevalence of WCH increased reaching 13% toward the end of pregnancy (33–42 weeks gestation). By this stage, WCH was as prevalent as true hypertension.

Strengths and Weaknesses

This study’s strengths include the systematic capture of all of the current literature and the inclusion of IPD data from 8 studies and >750 women. To our knowledge, this is the first comparison of self-monitored and office readings using data drawn from multiple studies, settings, and countries. Weaknesses include that 11 of the 21 studies may have had additional data on self-monitored and clinic readings but did not publish or provide it.18,39–48 In addition, IPD from the largest study to date were not available.37

All studies had some degree of methodological flaw (or lack of clarity), and only 2 studies used a self-monitoring device validated in the pregnant population. The validation of monitors in pregnancy and preeclampsia is important as pregnancy causes changes to the vasculature meaning that many generally validated monitors are inaccurate.49 Furthermore, the development of preeclampsia leads to significant and widespread hemodynamic disturbances, which have been shown to affect the accuracy of some BP monitors that are accurate in normal pregnancy.50–52 Only 5 monitors have been validated for home use in pregnancy.41,53–56

The selection of participants by contributing studies was generally clear although details of pregnancy stage were sometimes lacking and only 1 study was randomized. Attrition reporting was not always clear, and checking of self-monitored readings was not reported in any of the studies. Reporting of results was generally adequate (Table 2).

Studies were statistically and clinically heterogeneous reflecting diverse populations (health state, gestation of pregnancy) and clinical contexts (date and country of study). Many included studies were relatively small and published for a long time period (1991–2017), during which time there have been advances in BP monitoring technology. Most studies included in this review used monitors that have not been validated in pregnancy. The monitor used by both Brown et al,29 and Lo et al31 subsequently failed validation in the preeclamptic population. However, removing these studies from our analysis did not remove the observed heterogeneity. It is clear that further validation of BP monitors in the pregnant population is needed including individuals with preeclampsia and obesity.

A further potential cause of the observed heterogeneity could be differences in the populations studied. For example, both Lo et al15 and Ishikuro et al17 (Figures 4 and 5) observed normotensive healthy pregnant populations, and both Brown et al29 and Chandiramani et al16 (Figure 2; Figures S3–S5) selected women who had suspected hypertension; however, the clinic–self monitored differences in these study groups were opposing (Figure 2; Figures S3–S5). It may be

### Table 1. Studies Included in Analysis

<table>
<thead>
<tr>
<th>Author (Year) Country</th>
<th>Population</th>
<th>No. of Participants</th>
<th>Gestation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chandiramani (2006) United Kingdom</td>
<td>Suspected hypertension</td>
<td>100</td>
<td>Throughout pregnancy</td>
</tr>
<tr>
<td>Rey (2007) Canada</td>
<td>1) Hypertensive 2) Normotensive high risk of preeclampsia</td>
<td>100 20</td>
<td>Throughout pregnancy</td>
</tr>
<tr>
<td>Rey (2009) Canada</td>
<td>1) Chronic hypertension 2) Preeclampsia 3) Isolated office hypertension (WCH)</td>
<td>111 41 7*</td>
<td>Third trimester (28–38 wk gestation)</td>
</tr>
<tr>
<td>Sheehan (2016) United Kingdom</td>
<td>Hypertensive pregnancy</td>
<td>93*</td>
<td>Throughout pregnancy (12–40 wk)</td>
</tr>
<tr>
<td>Marko (2016) United States</td>
<td>1) Hypertensive 2) Normotensive high risk of preeclampsia 3) Isolated office hypertension (WCH)</td>
<td>111 41 7*</td>
<td>Throughout pregnancy (12–6 wk post-partum)</td>
</tr>
<tr>
<td>Tucker (2017) United Kingdom</td>
<td>Hypertensive pregnancy</td>
<td>201*</td>
<td>Throughout pregnancy (12–6 wk post-partum)</td>
</tr>
</tbody>
</table>

Summary data only

| Mooney (1991) United Kingdom | Any pregnancy | 35 | 30 wk |
| Ishikuro (2013) Japan | Healthy singleton pregnancy with no history of hypertension | 575 | 20 wk till 4 wk post-partum |

Table of the 10 studies with BP data for analysis. Eight studies were able to provide IPD and 2 further studies provided summary data. BP indicates blood pressure; IPD, individual patient data; and WCH, white coat hypertension.

*Data for both clinic and self-monitored readings were available as follows: Lo et al15 provided data for 102/146 participants, Rey et al16,17, provided data for 202 participants from combined studies (presented together), Sheehan et al34 provided data for 78 of 93 participants, Marko et al35 provided data from 47 of 50 participants, and Tucker et al35 provided data from 162 of 201 participants. Data were available from 758 participants (81% of the total participants in the studies included in the IPD).
that the monitor used, schedule of monitoring, or some other factor was more influential.

Overall, the data were representative of populations that may use home monitoring, either to detect hypertension in pregnancy (normotensive pregnancies\(^\text{31,35}\)), differentiate between true and WCH (suspected but not confirmed hypertension\(^\text{29,30}\)), or manage hypertension (women with gestational hypertension or preeclampsia\(^\text{30–32}\)).

**Comparison With the Previous Literature**

Clear SMBP thresholds for hypertension in pregnancy have not been established in the United Kingdom.\(^\text{23}\) Canadian guidelines recommend a self-monitored threshold of 135/85 mm Hg although it is unclear on what this is based, presumably the nonpregnant population.\(^\text{17,27}\) A sensitivity analysis using a threshold for hypertension of 135/85 mm Hg for home monitoring showed a slightly higher level of discordance with diagnosis based on clinic readings. However, subgroup analysis of women with hypertension (defined by clinic readings) showed that this group had a much larger home-office difference, suggesting that this group was selecting for a larger white coat effect and therefore lower thresholds may be appropriate.

Previous reports have suggested that the prevalence of WCH in pregnancy may be considerable.\(^\text{43,57}\) In the general population, the amount of white coat effect is higher in hypertensive groups compared with normotensive groups.\(^\text{24}\) This is thought to be because the higher average BP is more likely to result in variations above threshold and because this population may be more anxious about clinic results. This increase in white coat effect in hypertensive groups seems also to be true in pregnancy as several studies show high prevalence of WCH in hypertensive pregnancy.\(^\text{33,37,43,57}\) Some data suggest that women with WCH are at low risk of complications, but others that WCH reflects increased variability and hence risk.\(^\text{38}\) Further work is required to understand the true prognosis of WCH in pregnancy.

---

**Table 2. Methodological Details of the Included Studies**

<table>
<thead>
<tr>
<th>First Author</th>
<th>Type of Study</th>
<th>Clear Selection Criteria</th>
<th>Response Rate</th>
<th>Clinic Monitor</th>
<th>Same Ref Standard Across Sample</th>
<th>Self/Home Monitor</th>
<th>Validated for Use in Pregnancy</th>
<th>Adequate Checking of Home Readings</th>
<th>Regime Self-Monitoring</th>
<th>Time Between Comparisons</th>
<th>Blinding to Home Values</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brown et al(^\text{29})</td>
<td>Observational</td>
<td>Y</td>
<td>NC</td>
<td>Routine</td>
<td>mercury sphyg (phase V)</td>
<td>Y</td>
<td>Omron HEM 705CP</td>
<td>N</td>
<td>N</td>
<td>6× a day</td>
<td>Next day</td>
</tr>
<tr>
<td>Chandiramani et al(^\text{30})</td>
<td>Observational</td>
<td>Y</td>
<td>NC</td>
<td>Microlife 3BT10</td>
<td>Y</td>
<td>Microlife 3BT10</td>
<td>N</td>
<td>N</td>
<td>Not clear</td>
<td>Not clear</td>
<td>NC</td>
</tr>
<tr>
<td>Lo et al(^\text{31})</td>
<td>Observational</td>
<td>Y</td>
<td>NC</td>
<td>Omron HEM-705 and Mercury</td>
<td>N</td>
<td>Omron HEM-705CP</td>
<td>N</td>
<td>N</td>
<td>4 readings within 24 h</td>
<td>3 readings 24 h before home readings</td>
<td>Y</td>
</tr>
<tr>
<td>Rey et al(^\text{32})</td>
<td>Observational</td>
<td>Y</td>
<td>NC</td>
<td>Aneroid</td>
<td>Y</td>
<td>Aneroid</td>
<td>N</td>
<td>N</td>
<td>3×–7× a week</td>
<td>Same antenatal period</td>
<td>Y</td>
</tr>
<tr>
<td>Rey et al(^\text{33})</td>
<td>Observational</td>
<td>Y</td>
<td>NC</td>
<td>Aneroid</td>
<td>Y</td>
<td>Aneroid</td>
<td>N</td>
<td>N</td>
<td>3×–7× a week</td>
<td>Average of all self-monitored readings in the week preceding.</td>
<td>Y</td>
</tr>
<tr>
<td>Sheehan et al(^\text{34})</td>
<td>Observational</td>
<td>Y</td>
<td>NC</td>
<td>Routine</td>
<td>Y</td>
<td>Microlife WatchBPHome</td>
<td>Y</td>
<td>NC</td>
<td>Twice a day</td>
<td>Closest clinic reading*</td>
<td>N</td>
</tr>
<tr>
<td>Marko et al(^\text{35})</td>
<td>Controlled study</td>
<td>Y</td>
<td>NC</td>
<td>Routine</td>
<td>NC</td>
<td>NC</td>
<td>Y</td>
<td>NC</td>
<td>Closest clinic reading*</td>
<td>N</td>
<td></td>
</tr>
<tr>
<td>Tucker et al(^\text{36})</td>
<td>Observational</td>
<td>Y</td>
<td>NC</td>
<td>Routine</td>
<td>Y</td>
<td>Microlife WatchBPHome</td>
<td>Y</td>
<td>Monitor memory</td>
<td>3 d a week</td>
<td>Closest clinic reading*</td>
<td>N</td>
</tr>
<tr>
<td>Ishikuro et al(^\text{37})</td>
<td>Observational</td>
<td>Y</td>
<td>34%</td>
<td>Not clear</td>
<td>NC</td>
<td>Omron HEM747IC HEM708IC</td>
<td>N</td>
<td>NC</td>
<td>Every morning</td>
<td>Clinic BP every 4 wk</td>
<td>Y</td>
</tr>
<tr>
<td>Mooney et al(^\text{38})</td>
<td>Observational</td>
<td>Y</td>
<td>NC</td>
<td>Not clear</td>
<td>NC</td>
<td>Not Clear</td>
<td>Not known</td>
<td>NC</td>
<td>Not clear</td>
<td>Not clear</td>
<td>Y</td>
</tr>
</tbody>
</table>

Table showing the methodological details of the included studies. N indicates no; NC, not clear; and Y, yes.

*The nearest in time was considered the nearest in the 7 days around the first clinic reading (ie, in the 3 days before and 3 days after).
Perspectives

The monitoring of women with true chronic or gestational hypertension.5,13

If SMBP were to become commonplace in antenatal care, reference thresholds for self-monitored readings would be needed. Previous studies have examined the normal range of out-of-office BP during healthy pregnancy (predominantly using ambulatory BP monitoring) with varying...
conclusions. This is the first study to compare self-monitored and clinic readings across multiple studies. We found that self-monitored and clinic readings had little overall difference, suggesting that a self-monitored threshold equivalent to clinic threshold (currently 140/90 mm Hg) would be appropriate during pregnancy for normotensive women. Confirmation of this would require a study relating home BP to outcome. In addition, although we found little variation in mean differences, some women had clinically important differences between home and clinic readings, and therefore the prognostic significance of WCH and masked hypertension in pregnancy should also be considered. Subgroup analysis revealed that hypertensive pregnant women tended to have much larger home–office difference than normotensive pregnant women.

The clinical context of home monitoring is an important consideration. Whether the self-monitoring was additional to standard antenatal clinic visits, or being used as a replacement is relevant, as would which group of women are involved; those at risk of HDP, or those with HDP (ie, is the monitoring for diagnosis or management of hypertension?). For both groups, it would be reasonable to suggest that women with home readings of 140/90 mm Hg should be seen in clinic for safety. As current guidelines suggest starting medication for hypertension at 150/100 mm Hg, additional appointments in clinic may not be justified if clinic readings are likely to be <140/90 mm Hg. Hypertensive pregnant women defined on clinic pressures, however, may require a threshold similar to the hypertensive population outside pregnancy (135/85 mm Hg); previous studies have reported a high prevalence of WCH, and our subgroup analysis would support this.

Conclusions

This IPD analysis provides the best evidence to date on suitable thresholds for the diagnosis of HDP. Although showing heterogeneity between studies, overall there seems to be little difference between self-monitored and clinic readings. This evidence needs to be tempered by the knowledge that most monitors used in included studies were not validated and that monitoring schedules varied between studies. However, a finding of broad equivalence of clinic and home BP is in line with general population studies outside of pregnancy, unlike those with participants included on the basis of raised BP in...
the clinic. In turn, it suggests that home BP thresholds used for decision making in an unselected population in pregnancy should be equivalent to those currently used in clinic. SMBP, therefore, seems to have a role in ruling out WCH in those presenting with high clinic pressures. Understanding the true place of self-monitored BP in pregnancy will require further studies with validated monitors to confirm the equivalence of thresholds, including careful linkage to outcomes for women and their offspring. In addition, outcome studies are needed to better understand the prognosis of both WCH and masked hypertension in pregnancy.

Acknowledgments

We thank Dr Thierry Denolle, Dr Paul Mooney, Prof Kevin Dalton, Dr Ross-McGill, Prof William Rayburn, Dr Zuspan, Prof Jim Thornton, and Dr Janet Hirst who have provided advice and support and Carla Betts for administration support.

Sources of Funding

This article represents independent research commissioned by the National Institute for Health Research (NIHR) School of Primary Care Research (SPCR, SPCR project no. 171). The views expressed in this publication are those of the authors and not necessarily those of the National Health Service, the NIHR, or the Department of Health. R.J. McManus received support from an NIHR Professorship (NIHR- RP-02-12-015) and the NIHR Oxford Collaboration for Leadership in Applied Health Research and Care. C. Bankhead is supported by the NIHR Biomedical Research Centre, Oxford. The study was conceived by R.J. McManus who in collaboration with K.L. Tucker, C. Heneghan, J. Hodgkinson, and L. Mackillop gained the funding. The protocol was developed by K.L. Tucker, R.J. McManus, J. Hodgkinson, C. Bankhead, and R. Stevens with the advice and support of all authors. Literature searches were performed by N. Roberts, and review process completed by J. Hodgkinson and K.L. Tucker. Data were provided by E. Rey, C. Lo, K.S. Taylor, R.A. North, M. Chandiramani, R.S. Taylor, M. Brown, A. Khalil, K. Marko, and J. Waugh. Data cleaning was performed by K.L. Tucker, C. Bankhead, and K.S. Taylor, and statistical analysis was performed by K.L. Tucker and C. Bankhead with advice from R. Stevens. The first draft of the article was written by K.L. Tucker with R.J. McManus and subsequently edited and approved by all coauthors. All authors have read and approved the final manuscript.

Disclosures

The authors declare the following conflicts of interest: A. Khalil has read and approved the final manuscript for an app and software that enables pregnant women to monitor blood pressure at home. This was developed as part of the Copyright for an App and Software that enables pregnant women to monitor blood pressure at home. This was developed as part of

References


Novelty and Significance

**What Is New?**

- This study combined the currently available evidence on clinic and self-monitored blood pressure during pregnancy to consider thresholds for home monitoring.

**What Is Relevant?**

- There was little overall difference between self-monitored and clinic blood pressure readings, suggesting that appropriate thresholds for self-monitoring would be equivalent to clinic thresholds.

- White coat hypertension may be common toward the end of pregnancy, and more research is needed to assess the impact of this.

- More studies using monitors validated in pregnancy are needed.

**Summary**

Data from >750 pregnant women showed that there was little over all difference between self-monitored and clinic blood pressure readings. However, there were high levels of white coat hypertension toward the end of pregnancy.